RxDoctor Payments Data

Jennifer Jacobson

Psychiatric/Mental Health · Tucson, AZNPI 1730114976

Payments from drug & device makers

$4,340in general payments, 2019–2025

Across 48 payments — averaging $90.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$902
  • Alkermes, Inc.$670
  • Otsuka America Pharmaceutical, Inc.$556
  • Neurocrine Biosciences, Inc.$454
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$436
  • Johnson & Johnson$391
  • plus $931 from 6 others

What the payments were for

  • Food & beverage$4,29399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,340 in reported general payments places this provider in the 90th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$70,043
Medicare patients
84
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$54,500
TrintellixVortioxetine Hydrobromide12$5,647
Duloxetine Hcl122$2,615
Vilazodone Hcl24$2,148
Lamotrigine106$1,827
Bupropion XlBupropion Hcl56$1,633
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine62$1,310
Gabapentin50$1,307
Venlafaxine Hcl ErVenlafaxine Hcl46$1,282
Aripiprazole45$1,168
Mirtazapine28$1,119
Buspirone Hcl53$1,058
Escitalopram Oxalate76$978
Clonazepam89$945
Trazodone Hcl106$935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$383$54,50012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →